SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia
2 references·7 citing·42 second hop
Cost Effectiveness of Prophylactic Intravenous Immune Globulin in Chronic Lymphocytic Leukemia (1991)Cost Effectiveness of Prophylactic Intrav…Clinical decision analysis (2005)Clinical decision analysisWhose Utilities for Decision Analysis? (1990)Whose Utilities for Decision …Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model (2007)Cost-effectiveness of omalizu…Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B‐cell lymphoma (2005)Cost utility in the United St…EVALUATING THE COST-EFFECTIVENESS OF CLINICAL AND PUBLIC HEALTH MEASURES (1998)EVALUATING THE COST-EFFECTIVE…Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer. (1995)Economic evaluation of a rand…The standard gamble method: what is being measured and how it is interpreted. (1994)The standard gamble method: w…Healthy-years Equivalents versus Quality-adjusted Life Years (1993)Healthy-years Equivalents ver…Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems (1993)Changing the problem to fit t…Foundations of Cost-Effectiveness Analysis for Health and Medical Practices (1977)Measurement of health state utilities for economic appraisal (1986)Utilities and Quality-Adjusted Life Years (1989)Estimation of a Preference-Based Summary Score for the Patient-Reported Outcomes Measurement Information System: The PROMIS ® -Preference (PROPr) Scoring System (2018)Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review (2019)Use of the visual analogue scale for health state valuation: a scoping review (2023)Critical ratios and efficient allocation (1973)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)Cost-effectiveness ratios: in a league of their own (1994)Economics and the evaluation of health care programmes: generalisability of methods and implications for generalisability of results (2003)Healthcare Rationing by Proxy (2010)Review of Psychometric theory (2nd ed.). (1979)The Framing of Decisions and the Psychology of Choice (1981)Ignorance of Hedonic Adaptation to Hemodialysis: A Study Using Ecological Momentary Assessment. (2005)Misimagining the unimaginable: The disability paradox and health care decision making. (2005)On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review (2018)Theory of games and economic behavior (2019)The Markov Process in Medical Prognosis (1983)Markov Models in Medical Decision Making (1993)Multiattribute Utility Function for a Comprehensive Health Status Classification System (1996)The costs and consequences of omalizumab in uncontrolled asthma from a USA payer perspective (2010)Cost-effectiveness of asthma therapy: a comprehensive review (2014)Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations (2018)Recommendations of the Panel on Cost-Effectiveness in Health and Medicine (1996)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)What Is the Price of Life and Why Doesn't It Increase at the Rate of Inflation? (2003)Uncertainty (1990)Cost-Effectiveness in Health and Medicine (1996)Cost and quality under managed care: irreconcilable differences? (2000)Variation in the Estimation of Quality-adjusted Life-years by Different Preference-based Instruments (2003)Lessons from Cost-Effectiveness Research for United States Public Health Policy (2007)Choice Under Uncertainty: Problems Solved and Unsolved (1987)Preferences for outcomes in economic evaluation: An economic approach to addressing economic problems (1995)Are Methods for Estimating QALYs in Cost-Effectiveness Analyses Improving? (1997)Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care (1999)Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer (1991)Efficacy and Cost-effectiveness of Autologous Bone Marrow Transplantation in Metastatic Breast Cancer (1992)Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer (2002)Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer (2002)A Review and Meta-Analysis of Utility Values for Lung Cancer (2010)Utility approach to measuring health-related quality of life (1987)Non‐formal learning and tacit knowledge in professional work (2000)
this work references cited by second hop

References

  • 2005Clinical decision analysis1,579 cited
  • 1990Whose Utilities for Decision Analysis?382 cited

Cited by

  • 1994The standard gamble method: what is being measured and how it is interpreted.187 cited
  • 1998EVALUATING THE COST-EFFECTIVENESS OF CLINICAL AND PUBLIC HEALTH MEASURES147 cited
  • 2007Cost-effectiveness of omalizumab in adults with severe asthma: Results from the Asthma Policy Model111 cited
  • 1993Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems87 cited
  • 1995Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.87 cited
  • 1993Healthy-years Equivalents versus Quality-adjusted Life Years77 cited
  • 2005Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B‐cell lymphoma60 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work